Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

44.96EUR
9:39am EDT
Change (% chg)

€0.02 (+0.04%)
Prev Close
€44.94
Open
€44.94
Day's High
€45.04
Day's Low
€44.94
Volume
121,971
Avg. Vol
530,624
52-wk High
€45.50
52-wk Low
€10.75

Chart for

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.92
Market Cap(Mil.): €3,390.28
Shares Outstanding(Mil.): 75.41
Dividend: --
Yield (%): --

Financials

  ABLX.BR Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -1.71 -- --
ROI: -38.44 -7.75 12.60
ROE: -76.73 -10.55 14.49

BRIEF-Ablynx Completes Patient Recruitment In Phase IIb Respire Study Of ALX-0171

* ABLYNX COMPLETES PATIENT RECRUITMENT IN THE PHASE IIB RESPIRE STUDY OF ITS INHALED ANTI-RSV NANOBODY ALX-0171

Apr 30 2018

Sanofi sees new acquisitions and drugs reviving growth

PARIS Sanofi is betting on recent multibillion-dollar acquisitions and new drugs to drive "a new period of growth" from the second half of 2018 and offset persistent weakness in its key diabetes business.

Apr 27 2018

UPDATE 2-Sanofi sees new acquisitions and drugs reviving growth

* Shares down 1.5 percent (Adds quotes from CEO, analyst comment, shares)

Apr 27 2018

Healthcare group Sanofi to invest 350 million euros in Canada vaccine facility

PARIS French healthcare group Sanofi is investing 350 million euros ($432.4 million) in a Canadian vaccine facility, which the drugmaker said would help it meet growing demand in this area.

Apr 12 2018

Healthcare group Sanofi to invest 350 mln euros in Canada vaccine facility

PARIS, April 12 French healthcare group Sanofi is investing 350 million euros ($432.4 million) in a Canadian vaccine facility, which the drugmaker said would help it meet growing demand in this area.

Apr 12 2018

Novo Nordisk buys blood drug licence to boost anaemic biopharma business

COPENHAGEN Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) program in a bid to offset declining sales in its biopharmaceutical business.

Apr 05 2018

BRIEF-Ablynx Says Tender Offers By Sanofi To Acquire Co To Commence On April 4

* PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018

Mar 29 2018

BRIEF-Ablynx ‍Announces Topline Results From Phase II Study Of Vobarilizumab

* ‍ANNOUNCES TOPLINE RESULTS FROM PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS​

Mar 26 2018

BRIEF-Ablynx NV ‍Ablynx Commences Dosing In Its Phase II Study Of Alx-0171 In Hospitalised Japanese Infants With A Rsv Infection​

* ‍ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 02 2018

BRIEF-Reg-Sanofi Announces Receipt Of Antitrust Clearances In Connection With The Acquisition Of Ablynx

* Sanofi has received clearance from the Federal Cartel Office of Germany in accordance with the Act Against Restraints of Competition, applicable to Sanofi's proposed acquisition of Ablynx NV

Mar 01 2018

Earnings vs. Estimates